Home - Products - Angiogenesis - EGFR - Methyl 2,5-dihydroxycinnamate

Methyl 2,5-dihydroxycinnamate

CAS No. 63177-57-1

Methyl 2,5-dihydroxycinnamate( —— )

Catalog No. M27654 CAS No. 63177-57-1

Methyl 2,5-dihydroxycinnamate is an EGF receptor-associated tyrosine kinases inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 52 In Stock
5MG 52 In Stock
10MG 92 In Stock
25MG 187 In Stock
50MG 346 In Stock
100MG 517 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Methyl 2,5-dihydroxycinnamate
  • Note
    Research use only, not for human use.
  • Brief Description
    Methyl 2,5-dihydroxycinnamate is an EGF receptor-associated tyrosine kinases inhibitor.
  • Description
    Methyl 2,5-dihydroxycinnamate is an EGF receptor-associated tyrosine kinases inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    Apoptosis|BiP
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    63177-57-1
  • Formula Weight
    194.186
  • Molecular Formula
    C10H10O4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (643.73 mM)
  • SMILES
    COC(=O)\C=C\c1cc(O)ccc1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Oida Y, et al. Induction of BiP, an ER-resident protein, prevents the neuronal death induced by transient forebrain ischemia in gerbil. Brain Res. 2008 May 7;1208:217-24.
molnova catalog
related products
  • NRC-2694

    NRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR). It has anti-cancer and anti-proliferative properties.

  • O-Nornuciferine

    O-Nornuciferine reveals distinct in vitro hERG blockages measured in HEK293 cells with the IC50 value of 2.89 uM.

  • Falnidamol

    Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. It displays >1000-fold lower potency against ErbB2 (IC50=3.4 μM) and other related tyrosine kinases (IC50>10 μM).